Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer

Lung Cancer

Volumn 55, Issue 3, 2007, Pages 329-336

  Kim, Kyoung Ju ^a   Ahn, Yong Chan ^a   Lim, Do Hoon ^a   Han, Joungho ^a   Park, Keunchil ^a   Park, Joon Oh ^a   Kim, Kwhanmien ^a   Kim, Jhingook ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Non small cell lung cancer; Prognosis; Radiochemotherapy; Surgery

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 33847323153     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.10.024     Document Type: Article

References (23)

1. Patterson G.A., Piazza D., Pearson F.G., Todd T.R., Ginsberg R.J., and Goldberg M. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg 43 (1987) 155-159
2. Naruke T., Goya T., Tsuchiya R., and Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 46 (1988) 603-610
3. Martini N., and Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 67 (1987) 1037-1049
4. Ratto G.B., Mereu C., and Motta G. The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer. Chest 93 (1988) 807-813
5. Pearson F.G., DeLarue N.C., Ilves R., Todd T.R., and Cooper J.D. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 83 (1982) 1-11
6. Coughlin M., Deslauriers J., Beaulieu M., Fournier B., Piraux M., and Rouleau J. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg 40 (1985) 556-560
7. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., and van Houtte P. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
8. Sause W., Kolesar P., Taylor S.I., Johnson D., Livingston R., and Komaki R. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
9. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., and Menker H. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16 (1998) 622-634
10. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi III A.T., and Weick J.K. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
11. Weitberg A.B., Yashar J., Glicksman A.S., Posner M., Cummings F., and Browne M. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer 29A (1993) 511-515
12. Turrisi A.T., Scott C.B., Rusch V.R., Albain K.S., Shepherd F.A., and Smith C. Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139,RTOG (9309). Int J Radiat Oncol Biol Phys 57 (2003) S125-S126
13. Ahn Y.C., Park K., Kim D.Y., Kim K.M., Kim J., and Shim Y.M. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol 40 (2001) 588-592
14. Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor IV S.G., and Reddy S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47 (1989) 669-675 (Discussion 76-7)
15. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., and Green M.R. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 109 (1995) 473-483 (Discussion 83-5)
16. Martini N., Kris M.G., Flehinger B.J., Gralla R.J., Bains M.S., and Burt M.E. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55 (1993) 1365-1373 (Discussion 73-4)
17. Mathisen D.J., Wain J.C., Wright C., Choi N., Carey R., and Hilgenberg A. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 111 (1996) 123-131 (Discussion 131-3)
18. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., and von Briel C. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 (2003) 1752-1759
19. Bueno R., Richards W.G., Swanson S.J., Jaklitsch M.T., Lukanich J.M., and Mentzer S.J. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70 (2000) 1826-1831
20. Choi N.C., Carey R.W., Daly W., Mathisen D., Wain J., and Wright C. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15 (1997) 712-722
21. Bonner J.A., McGinnis W.L., Stella P.J., Marschke Jr. R.F., Sloan J.A., and Shaw E.G. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 82 (1998) 1037-1048
22. Junker K., Thomas M., Schulmann K., Klinke F., Bosse U., and Muller K.M. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123 (1997) 469-477
23. Robinson L.A., Wagner Jr. H., and Ruckdeschel J.C. Treatment of stage IIIA non-small cell lung cancer. Chest 123 (2003) 202S-220S